Donglin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Donglin Zhang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Chuanhu Xi
School of Pharmacy Wannan Medical College Wuhu China
1 shared publicationChunyan Liu
School of Pharmacy Wannan Medical College Wuhu China
1 shared publication- Guodong Wang
School of Pharmacy, Wannan Medical College, Wuhu 241002, China
1 shared publication Jun Han
School of Pharmacy Wannan Medical College Wuhu China
1 shared publication- Lei Zhu
Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, Georgia
1 shared publication Lina Liu
Department of Thyroid and Breast Surgery The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College Wuhu China
1 shared publication
Latest Publications
- Open Access
- 22 April 2025
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 13 (3) , e70094
Burdock Fructooligosaccharide Protects Against Diabetic Nephropathy in Mice by Regulating Nrf2 Signaling
Diabetic nephropathy (DN) is a common complication of diabetes mellitus, with oxidative stress playing a critical role in its development. Burdock fructooligosaccharide (BFO), a major compound in Burdock, exhibits antioxidative effects. However, its mechanisms of action and effects on diabetic nephropathy are not clear enough. This study aims to explore the mechanisms of BFO and its impact on streptozotocin‐induced diabetic nephropathy in mice. Male C57BL/6J mice were randomly divided into normal control, DN, and BFO groups. Relevant serum biochemical parameters were detected using kits. Renal injury was evaluated through fluorescence microscopy, histopathology, and transmission electron microscopy. Nrf2/HO‐1 signaling was analyzed via quantitative real‐time PCR, western blotting, and immunohistochemistry. In DN mice, BFO significantly reduced fasting blood glucose, kidney index, urine protein, serum creatinine, blood urea nitrogen, total cholesterol, triglyceride, and low‐density lipoprotein cholesterol, while significantly increasing high‐density lipoprotein, SOD, and CAT levels. Additionally, BFO protected against streptozotocin‐induced renal injury, restored podocyte function, increased both mRNA and protein expression of Nrf2, HO‐1, and Bcl‐2, and decreased those of Bax. In conclusion, BFO can be used to treat streptozotocin‐induced renal injury in mice and is a promising candidate for diabetic nephropathy treatment.
- 22 April 2025
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 13 (3) , e70094
Open AccessBurdock Fructooligosaccharide Protects Against Diabetic Nephropathy in Mice by Regulating Nrf2 Signaling
Diabetic nephropathy (DN) is a common complication of diabetes mellitus, with oxidative stress playing a critical role in its development. Burdock fructooligosaccharide (BFO), a major compound in Burdock, exhibits antioxidative effects. However, its mechanisms of action and effects on diabetic nephropathy are not clear enough. This study aims to explore the mechanisms of BFO and its impact on streptozotocin‐induced diabetic nephropathy in mice. Male C57BL/6J mice were randomly divided into normal control, DN, and BFO groups. Relevant serum biochemical parameters were detected using kits. Renal injury was evaluated through fluorescence microscopy, histopathology, and transmission electron microscopy. Nrf2/HO‐1 signaling was analyzed via quantitative real‐time PCR, western blotting, and immunohistochemistry. In DN mice, BFO significantly reduced fasting blood glucose, kidney index, urine protein, serum creatinine, blood urea nitrogen, total cholesterol, triglyceride, and low‐density lipoprotein cholesterol, while significantly increasing high‐density lipoprotein, SOD, and CAT levels. Additionally, BFO protected against streptozotocin‐induced renal injury, restored podocyte function, increased both mRNA and protein expression of Nrf2, HO‐1, and Bcl‐2, and decreased those of Bax. In conclusion, BFO can be used to treat streptozotocin‐induced renal injury in mice and is a promising candidate for diabetic nephropathy treatment.